Desmopressin testing in von Willebrand disease: Lowering the burden

Authors :: Jessica M. Heijdra
Ferdows Atiq
Wala Al Arashi
Quincy Kieboom
Esmee Wuijster
Karina Meijer
Marieke J. H. A. Kruip
Frank W. G. Leebeek
Marjon H. Cnossen
in collaboration with the OPTI‐CLOT Study Group
Source :: Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Publication Year :: 2022
Publisher :: Elsevier, 2022.
Abstract: Abstract Background Individuals with von Willebrand disease (VWD) require desmopressin testing because of interindividual response differences. However, testing is burdensome, while not all patients may need extensive testing. Objectives To provide von Willebrand factor (VWF) cutoffs that predict desmopressin nonresponse and thereby identify individuals who do not need extensive testing in a retrospective cohort. We validated these cutoffs in a prospective cohort. Patients and Methods We included 376 patients (Type 1 VWD with VWF activity [VWF:Act]